Global Stem Cell Group Operations
The Company envisions the ability to improve "health-span" through the discovery and developments of new cellular therapy products, and cutting-edge technology.
Global Stem Cells Group, as almost everyone else in the world, was severely affected by the covid 19 pandemic. As we look to recover in 2022, we are integrating every aspect of the regenerative medicine industry. During 2022, we plan to add manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever.
We believe this strategy will allow us the ability to increase our current revenues and create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform here are our main projects and revenue generators for 2022 and beyond.
Permanent Treatment Center of Excellence and Physician Training in Istanbul, Turkey
Cell Therapy Product Manufacturing Facility in Cancun Mexico
The Cancun facility that is to begin operations in July of 2022 has been accredited both by the Mexican General Health Council and Cofepris (Mexican FDA). GSCG's processing operation is in the well-known HELLIMEX, S.A. DE CV building, a high-rise office of leased suites that provide a multitude of other professional services.
Cell Therapy Product manufacturing facility in Dubai UAE
Similar to Cancun, we are in the process of building out a leased suite and equipping this facility in the well-known healthcare city DUBAI UAE. This facility will serve patients and physicians from the Middle East and Asia and will have the same capabilities as our Cancun counterpart.
non-particles that play a pivotal role in cell-to-cell communication that
are involved in a wide range of physiological processes. Exosomes play an
important role in the transfer of proteins and other bioactive molecules
regeneration of tissue. Their anti-inflammatory and immunomodulatory
properties mean that it is difficult for them to be rejected by the body.
Additionally, they increase blood flow to the vital organs that need it
? CELLGENIC LUMA (Lyophilized Exosomes) is derived from human umbilical cord
mesenchymal stem cells and includes potent growth factors, peptides,
coenzymes, minerals, amino acids, vitamins and UV radiation reducing
agents for skin revitalization. Exosomes are extracellular vesicles, which
? VITANOVAS is a mobile IV infusion company that provides in-home treatments
harnesses the natural and powerful restorative capabilities of adipose
tissue. It is a cutting-edge tool that utilizes micrograft technology to
harness the natural and powerful restorative capabilities of adipose
tissues. This is a precise system that is able to process a stem cell
sample from adipose tissue in less than half of the time that it would
take a physician to do so through traditional means. This allows the
patient to be more comfortable throughout the shorter procedure, as less
anesthesia is also required than when operating under traditional means.
The GCell is a minimally invasive, portable machine that allows physicians
to fully unlock the potential of regenerative medicine as a component in
? CELLGENIC SVF is an isolation kit system that has all the ingredients and
? CELLGENIC BONE MARROW Cell isolation protocols usually include density
gradient centrifugation. With careful attention to detail the BMC system
gently and precisely processes bone marrow aspirate for the purest
concentration of these cells at the point of care. BMC is part of a
developmental effort to provide an effective therapy that is low risk. It
reduce inflammation. As a concentrated source of autologous platelets, PRP
contains several growth factors and other cytokines that can stimulate the
We are committed to the protection of our intellectual property of proprietary products and process as well as trademarks and other methods described below.
On February 19, 2019, the U.S. Patent and Trademark Office ("USPTO") filed US service trademark, 5,682,488 which claims exclusive us of "ISCCA" as INTERNATIONAL SOCIETY FOR STEM CELL APPLICATION to Stem Cell Training Inc a Florida Corporation.
On April 30, 2019, the U.S. Patent and Trademark Office ("USPTO") granted US service trademark, 5,739,089 which claims exclusive us of "ISCCA" as INTERNATIONAL SOCIETY FOR STEM CELL APPLICATION to Stem Cell Training Inc a Florida Corporation.
We own proprietary protocols for the harvesting and isolation of Stem Cells Derived from the adipose tissue and Bone marrow.
We also own proprietary standard operating procedures for the manufacturing of allogeneic cellular therapy products derived from perinatal tissue.
While there are particular or specific competitors in any one of these areas, no one is currently providing the full service one stop solution for such a complete range of offerings in this industry as we are.
Furthermore, we compete by becoming a resource, creating standards of practice, advancing the Stem Cell field in general, and by connecting associates and partners in many different aspects of the business.
Meso Numismatics, Inc., has established a growing numismatics operation Meso Numismatics focuses on the Central American Caribbean region with a concentration of products surrounding Mesoamerica (Mexico to Panama).
The Company's inventory is comprised of roughly 50% coins / medals and 50% paper money. The Company has a meticulous process for the acquisition and sales process for each coin item. The Company specializes in coins from the Meso region, but also acquires coins and medals from elsewhere around the world.
As indicated above, paper money makes up approximately 50% of Meso's inventory. The process of acquiring paper money almost mirrors that of coins / medals.
To our knowledge, Meso Numismatics has the only banknote scanner on the market. The technology, mostly utilized by numismatists, quickly assesses all the information about a banknote and almost instantly displays the information, along with a replica banknote from the database.
Results of Operations for the Three Months Ended March 31, 2022 and 2021.
Listed below are the revenues, cost of revenues and gross profits by Company for the three months ended March 31, 2022:
Professional fees increased by $281,952 for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to $55,800 in consulting and $193,000 in audit and accounting expenses.
General and administrative expense increase by $91,308 for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.
We recorded a net loss of $1,676,964 for the three months ended March 31, 2022, as compared with a net loss of $472,307 for the same in 2021.
Since inception, the Company has financed its operations through private placements and convertible notes. The following is a summary of the cash and cash equivalents as of March 31, 2022 and December 31, 2021.
© Edgar Online, source Glimpses